

Press release  
02 December 2014



## **BioVersys and Enamine Announce Extension of Drug Discovery Collaboration to Address Multidrug-Resistant Bacterial Infections**

**December 2<sup>nd</sup> 2014, Kiev, Ukraine & Basel, Switzerland:** Enamine Ltd. and BioVersys AG announced today the extension of their drug discovery collaboration for the 4<sup>th</sup> consecutive year. Since the start of the collaboration Enamine has provided expertise in screening of compounds and chemistry know-how for hit finding activities and optimization. BioVersys has brought its unique approach and knowledge of antimicrobial resistance into the partnership. The new agreement covers further involvement of Enamine's HTS platform and ADME profiling capabilities. Enamine has expanded its team of medicinal chemists to support the collaboration.

Financial details were not disclosed. The IP generated by the collaboration is owned by BioVersys.

Mr. Michael Bossert, Head of Strategic Alliances at Enamine, commented: "There is a high medical need for new treatments against bacterial infections that has emerged in recent years due to the resistance of bacterial strains against existing antibiotics. We are very pleased to be collaborating with BioVersys, an innovative biopharmaceutical company in the field of bacterial resistance."

Dr. Marcel Tigges, Co-Founder and CSO at BioVersys, added: "We have established a network of partnerships with key players in the areas where we need specific external expertise. Valuing Enamine's people, chemistry expertise and flexibility, our decision to extend the collaboration was a logical move".

Dr. Marc Gitzinger, Co-Founder and CEO at BioVersys, commented: "Our research programs are benefitting significantly from the productive partnership established with Enamine. The Company's set-up and ability to respond to our requirements and timelines demonstrates that Enamine is a reliable partner providing high quality services. We look forward to continuing our collaboration and to reaching the next milestones."

**ENDS**

**Notes to editors**

**About BioVersys AG**

The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company's award-winning TRIC technology it will be possible to restore the efficacy of established antibiotics. BioVersys addresses the high unmet medical need for new treatments of life-threatening bacterial infections that emerged in recent years due to antibiotic resistance. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is on Nosocomial Infections (hospital infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille BioVersys aims to develop an effective treatment against Tuberculosis. [www.bioversys.com](http://www.bioversys.com)

### **About Enamine**

Established in Kiev in 1991, Enamine is a medicinal chemistry driven company, provider of innovative screening libraries, building blocks, comprehensive chemistry support in hit development, and integrated drug discovery services. Enamine's design and synthesis capabilities allow the addition of more than 250,000 new organic compounds to its catalogue each year. Enamine offers collaborative expertise to exclusively design and supply libraries of new, potentially bioactive organic compounds. Enamine serves the pharmaceutical, agrochemical, cosmetic, nutritional and petrochemical industries.

[www.enamine.net](http://www.enamine.net)

### **Contacts:**

#### **Enamine**

Michael Bossert  
Head Strategic Alliances  
E: [m.bossert@enamine.net](mailto:m.bossert@enamine.net)  
T: +38 044 537 32 18

#### **BioVersys**

Dr. Marcel Tigges,  
Chief Science Officer  
E: [marcel.tigges@bioversys.com](mailto:marcel.tigges@bioversys.com)  
T: +41 61 633 22 51

#### **Media enquiries**

Lorna Cuddon, Zyme Communications  
E: [Lorna.cuddon@zymecommunications.com](mailto:Lorna.cuddon@zymecommunications.com)  
T: +44 (0)7811996942